TG Therapeutics, Inc. (TGTX)
$54.37+0.06%Close
SELLBEAR · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8.3B
- Beta
- 1.80
- P/E (TTM)
- 17.86
- Short % float
- 22.68%
- Days to cover
- 15.0
- SI change
- +1.6%
- 1W
- +2.68%
- 1M
- +2.51%
- vs SPY 1W
- +2.82%
- vs SPY 1M
- +0.00%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 53
- VALUE
- 18
- GROWTH
- 46
- GARP
- 76
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC43.4%
REV YoY-
ROE72.3%
EPS YoY-
ROA26.9%
GROSS82
OP17
NET55
[VALUATION]
P/E TTM17.86
P/E FWD21.74
SECTOR PE20.48
INDUSTRY PE13.99
P/B12.76
P/FCF-
EV/EBITDA64.02
EV/EBIT-
PEG0.93
FCF YIELD-
RISK
INT COV-
D/E124.89
ALTMAN Z-
CURR RATIO4.27
ND/EBITDA-
BETA1.80
Company news
FAQ
- What is LOPJLB’s current signal on TGTX?
- LOPJLB’s latest quantitative signal on TG Therapeutics, Inc. (TGTX) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is TGTX in?
- TG Therapeutics, Inc. (TGTX) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does TG Therapeutics, Inc. (TGTX) do?
- Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant inv…